Lukashevich, V <br/><br/>
Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial.  [electronic resource] 

 -  Diabetes, obesity & metabolism  Oct 2011 
 - 947-54 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1463-1326 
<br/><br/><label>Standard No.: </label>10.1111/j.1463-1326.2011.01467.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adamantane--administration & dosage<br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Diabetes Mellitus, Type 2--drug therapy<br/>Diabetic Nephropathies--metabolism<br/>Dipeptidyl-Peptidase IV Inhibitors--administration & dosage<br/>Double-Blind Method<br/>Female<br/>Glycated Hemoglobin--drug effects<br/>Humans<br/>Kidney Failure, Chronic--metabolism<br/>Male<br/>Middle Aged<br/>Nitriles--administration & dosage<br/>Prospective Studies<br/>Pyrrolidines--administration & dosage<br/>Treatment Outcome<br/>Vildagliptin<br/>Young Adult